This study evaluated the efficacy and toxicity of combination chemotherapy with paclitaxel, oxaliplatin, 5-fluorouracil and leucovorin (POFL) in patients with recurrent or metastatic gastric cancer.
Methods:
One hundred and thirty-eight patients with histologically confirmed recurrent or metastatic gastric adenocarcinoma were treated with the POFL regimen: paclitaxel at a dose of 135 mg/m2 as a 3-hour intravenous infusion on day 1, oxaliplatin 85 mg/m2 and leucovorin 400 mg/m2 as an intravenous infusion over 2 hours on day 1, followed by 5-fluorouracil 2,400 mg/m2 as an infusion over a 46-hour period on 3 consecutive days, in a 2-week cycle.
Results:
Twelve patients could not be evaluated for response because of the absence of any measurable lesions or early discontinuation of therapy, so responses were assessed in 126 patients. The overall objective response rate was 56.3% (95% CI, 47.5%-64.9%). The median time to progression was 6.7 months (95% CI, 5.8-7.6 months), and the median overall survival was 12.6 months (95% CI, 11.3-13.9 months). The most common grade 3 and 4 toxicities were neutropenia (50.7%), peripheral neurotoxicity (16.7%) and alopecia (27.5%).
Conclusions:
Combination chemotherapy with POFL offers a new, active and safe approach to the treatment of recurrent or metastatic gastric cancer.
JemalABrayFCenterMMFerlayJWardEFormanD. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69-90.
2.
JemalASiegelRWardEHaoYXuJThunMJ. Cancer statistics, 2009. CA Cancer J Clin. 2009;59(4):225-249.
3.
GlimeliusBEkströmKHoffmanKet al. Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol. 1997;8(2):163-168.
4.
MuradAMSantiagoFFPetroianuARochaPRRodriguesMARauschM. Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer. 1993;72(1):37-41.
5.
KimNKParkYSHeoDSet al. A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer. Cancer. 1993;71(12):3813-3818.
6.
YchouMAstreCRouanetPet al. A phase II study of 5-fluorouracil, leucovorin and cisplatin (FLP) for metastatic gastric cancer. Eur J Cancer. 1996;32A(11):1933-1937.
7.
VanhoeferURougierPWilkeHet al. Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group. J Clin Oncol. 2000;18(14):2648-2657.
8.
PreusserPWilkeHAchterrathWet al. Phase II study with the combination etoposide, doxorubicin, and cisplatin in advanced measurable gastric cancer. J Clin Oncol. 1989;7(9):1310-1317.
9.
ZaniboniABarniSLabiancaRet al. Epirubicin, cisplatin, and continuous infusion 5-fluorouracil is an active and safe regimen for patients with advanced gastric cancer. An Italian Group for the Study of Digestive Tract Cancer (GISCAD) report. Cancer. 1995;76(10):1694-1699.
10.
De VitaFOrdituraMMatanoEet al. A phase II study of biweekly oxaliplatin plus infusional 5-fluorouracil and folinic acid (FOLFOX-4) as first-line treatment of advanced gastric cancer patients. Br J Cancer. 2005;92(9):1644-1649.
11.
LeeHHHurHKimSHParkARKimWJeonHM. Outcomes of modified FOLFOX-6 as first line treatment in patients with advanced gastric cancer in a single institution; retrospective analysis. Cancer Res Treat. 2010;42(1):18-23.
12.
WagnerADGrotheWHaertingJKleberGGrotheyAFleigWE. Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol. 2006;24(18):2903-2909.
13.
CaplowMShanksJRuhlenR. How taxol modulates microtubule disassembly. J Biol Chem. 1994;269(38):23399-23402.
14.
AjaniJAFairweatherJDumasPPattYZPazdurRMansfieldPF. Phase II study of Taxol in patients with advanced gastric carcinoma. Cancer J Sci Am. 1998;4(4):269-274.
15.
YamadaYShiraoKOhtsuAet al. Phase II trial of paclitaxel by three-hour infusion for advanced gastric cancer with short premedication for prophylaxis against paclitaxel-associated hypersensitivity reactions. Ann Oncol. 2001;12(8):1133-1137.
16.
YamaguchiKTadaMHorikoshiNet al. Paclitaxel Gastric Cancer Study Group in Japan. Phase II study of paclitaxel with 3-h infusion in patients with advanced gastric cancer. Gastric Cancer. 2002;5(2):90-95.
17.
GuJYamamotoHLuXet al. Low-dose oxaliplatin enhances the antitumor efficacy of paclitaxel in human gastric cancer cell lines. Digestion. 2006;74(1):19-27.
18.
LinRBFanNFGuoZQWangXJLiuJChenL. A phase II study of 5-fluorouracil/leucovorin in combination with paclitaxel and oxaliplatin as first-line treatment for patients with advanced gastric cancer. J Chemother. 2008;20(6):744-748.
19.
BangY-JVan CutsemEFeyereislovaAet al. ToGA Trial Investigators. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376(9742):687-697.
20.
Van CutsemEMoiseyenkoVMTjulandinSet al. V325 Study Group. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol. 2006;24(31):4991-4997.
21.
JeungHCRhaSYKimYTNohSHRohJKChungHC. A phase II study of infusional 5-fluorouracil and low-dose leucovorin with docetaxel for advanced gastric cancer. Oncology. 2006;70(1):63-70.
22.
ParkSHLeeWKChungMet al. Paclitaxel versus docetaxel for advanced gastric cancer: a randomized phase II trial in combination with infusional 5-fluorouracil. Anticancer Drugs. 2006;17(2):225-229.
23.
KimJGSohnSKSongHSet al. Multicenter phase II study of weekly paclitaxel plus cisplatin combination chemotherapy in patients with advanced gastric cancer. Cancer Chemother Pharmacol. 2007;60(6):863-869.
24.
GadgeelSMShieldsAFHeilbrunLKet al. Phase II study of paclitaxel and carboplatin in patients with advanced gastric cancer. Am J Clin Oncol. 2003;26(1):37-41.
25.
HoneckerFKollmannsbergerCQuietzschDet al. Phase II study of weekly paclitaxel plus 24-h continuous infusion 5-fluorouracil, folinic acid and 3-weekly cisplatin for the treatment of patients with advanced gastric cancer. Anticancer Drugs. 2002;13(5):497-503.
26.
LokichJJSonnebornHAndersonNRet al. Combined paclitaxel, cisplatin, and etoposide for patients with previously untreated esophageal and gastroesophageal carcinomas. Cancer. 1999;85(11):2347-2351.
27.
SakamotoJMatsuiTKoderaY. Paclitaxel chemotherapy for the treatment of gastric cancer. Gastric Cancer. 2009;12(2):69-78.
28.
LeeHJChoDYParkJCet al. Phase II trial of biweekly paclitaxel plus infusional 5-fluorouracil and leucovorin in patients with advanced or recurrent inoperable gastric cancer. Cancer Chemother Pharmacol. 2009;63(3):427-432.
29.
Al-BatranSEHartmannJTProbstSet al. Arbeitsgemeinschaft Internistische Onkologie. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol. 2008;26(9):1435-1442.
30.
CunninghamDStarlingNRaoSet al. Upper Gastrointestinal Clinical Studies Group of the National Cancer Research Institute of the United Kingdom. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med. 2008;358(1):36-46.
31.
KimHSKimJHKimHJet al. Oxaliplatin, 5-fluorouracil and leucovorin (modified FOLFOX-6) as first-line chemotherapy for advanced gastric cancer patients with poor performance status. Oncol Lett. 2012;3(2):425-428.
32.
GuoZWangXLinRet al. Paclitaxel-based regimens as first-line treatment in advanced gastric cancer. J Chemother. 2015; 27(2):94-98.
